Market open

Nektar Therapeutics/NKTR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Ticker

NKTR
Trading on

Industry

Pharmaceuticals

Employees

137

NKTR Metrics

BasicAdvanced
$250M
Market cap
-
P/E ratio
-$0.90
EPS
0.67
Beta
-
Dividend rate
$250M
0.67
$1.93
$0.41
957K
5.149
4.782
248.807
275.582
-5.34%
-20.16%
-128.02%
2.865
3.56
3.14
-1.522
6.17%
-44.63%
-4.05%
-29.94%

What the Analysts think about NKTR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.

NKTR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NKTR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy NKTR

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nektar Therapeutics stock?

Nektar Therapeutics (NKTR) has a market cap of $250M as of October 14, 2024.

What is the P/E ratio for Nektar Therapeutics stock?

The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of October 14, 2024.

Does Nektar Therapeutics stock pay dividends?

No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of October 14, 2024.

When is the next Nektar Therapeutics dividend payment date?

Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.

What is the beta indicator for Nektar Therapeutics?

Nektar Therapeutics (NKTR) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.